Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Colorectal Neoplasms 4Solid Tumor 3Stomach Neoplasms 2Melanoma 2Endometrial Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Metastatic Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma × tislelizumab × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡